Sibyl Wray, MD Neurology, PC

Knoxville, Tennessee 37934

1 studies enrolling now · 11 studies all time

What they study most

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Relapse Remitting Multiple Sclerosis, Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Relapsing-Remitting Multiple Sclerosis

Studies at this site

• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Recruiting now
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation — Running, not enrolling
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab — Running, not enrolling
• Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. — Completed
• A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis — Completed
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — NO_LONGER_AVAILABLE